The BANOOK Group will hold a Lunch & Learn session on Tuesday, Jan. 23rd, 2018 at 12:00 pm in the Philippe Walker Auditorium.
The seminar title of Drs. Pascal Voiriot and Mathieu Felices’ presentation will be:
“Cardiac safety assessment in early drug development: significance of preclinical testing, and paradigm change regarding QT assessment and ECG PK/PD modelling”
As a luncheon will be provided by BANOOK, kindly RSVP before Thursday, Jan. 18th to Terry Grassetti at firstname.lastname@example.org
Dr. Claude Bertrand is the General Director R&D and Chief Scientific Officer at Servier. Prior to this role, Dr. Bertrand was Executive Vice-President for Research & Development, Chief Scientific Officer with a focus on Oncology, Neurology and Endocrinology at Ipsen, France (2011). In 2004, Dr. Bertrand joined AstraZeneca as Vice-President Discovery for Respiratory & Inflammation Research at Alderley Park, UK and in 2005, was appointed Global Senior Vice President for Respiratory & Inflammation Research Area overseeing R&D activities at three sites in the UK and Sweden.
Claude Bertrand has published more than 70 papers in peer-reviewed journals, has authored 20 chapters and has presented more than 100 communications at scientific meetings.
Dr. Claude Bertrand is a graduate in pharmacy from the University of Strasbourg, France where he also obtained his PhD in immuno-pharmacology and neurogenic inflammation. After a 2-year post-doctoral appointment at University of California, San Francisco, Claude Bertrand joined the Allergy and Asthma Unit at Ciba-Geigy (now known as Novartis) in Basel.More Details